A long-term study published in a recent issue of the Journal of Palliative Medicine found that Eli Lilly’s non-narcotic prescription drug Cymbalta (duloxetine HCl) is as safe and well-tolerated as current routine care that uses one or more medications for the management of pain caused by diabetic nerve damage. Study findings also show that Cymbalta did not adversely affect the progression of diabetes or many of the complications associated with the illness, such as damage to the nerves, kidneys and eyes.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately half of all people with diabetes have some form of nerve damage, or neuropathy. Not all, however, will develop symptoms.
Cymbalta is approved in the United States for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. It is not approved for use in pediatric patients.
For full patient information, visit the Web site at www.Cymbalta.com.